Business
InspireMD Announces FDA Approval of Investigational Device Exemption Application for CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System
MIAMI, May 01, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that the U.S. Food and Drug Administration (“FDA”) has approved the company’s Investigational Device Exemption (“IDE”) Application to initiate the CGUARDIANS III pivotal study of its SwitchGuard neuro protection system (“NPS”), including next generation enhancements from our prior IDE approval for
About this update from Inspiremd Inc.
[{"type":"image","alt":"InspireMD Inc.","displaySize":"","headline":null,"caption":"InspireMD Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":178,"height":24,"url":"https://media.zenfs.com/en/globenewswire.com/291f6cac2fbf0704acd61c88071899d5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2oTbfyHon8MiI_bmdzR_wQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTI4/https://media.zenfs.com/en/globenewswire.com/291f6cac2fbf0704acd61c88071899d5","width":178,"height":24}},"lazy":false},{"type":"text","content":"MIAMI, May 01, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that the U.S. Food and Drug Administration (“FDA”) has approved the company’s Investigational Device Exemption (“IDE”) Application to initiate the CGUARDIANS III pivotal study of its SwitchGuard neuro protection system (“NPS”), including next generation enhancements from our prior IDE approval for use with its CGuard Prime 80 cm stent platform, in transcarotid artery revascularization (“TCAR”) procedures.","length":609,"tagName":"p"},{"type":"text","content":"Patrick Geraghty, M.D., professor of surgery and radiology, section of vascular surgery at Washington University School of Medicine in St. Louis, MO, and Patrick Muck, M.D., program director and chief of vascular surgery at Good Samaritan Hospital in Cincinnati, OH, who previously led the CGUARDIANS II trial as co-lead investigators, will continue in the roles for the CGUARDIANS III trial.","length":392,"tagName":"p"},{"type":"text","content":"“The approval of our CGUARDIANS III IDE represents a meaningful advancement in our quest to offer the full TCAR tool kit leveraging our best-in-class CGuard Prime 80 cm stent platform for unmatched stroke prevention and carotid disease management,” said Marvin Slosman, CEO of InspireMD. “We look forward to the efficient execution of this important study as we target U.S. commercial launch of the SwitchGuard NPS in 2027, if approved.”","length":437,"tagName":"p"},{"type":"text","content":"For additional information: https://clinicaltrials.gov/study/NCT07277296","length":72,"tagName":"p"},{"type":"text","content":"About InspireMD, Inc.InspireMD seeks to utilize its proprietary MicroNet ™ mesh technology to make its products the industry standa...